AC
WVE icon

Aristides Capital’s Wave Life Sciences WVE Stock Holding History

Aristides Capital’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-19,007
Closed -$60K – 299
2021
Q4 		$60K Buy
+19,007
New +$78.9K 0.03% 257

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Aristides Capital's WVE Position: Q1 2022 in Review

Aristides Capital sold out of Wave Life Sciences (WVE) in Q1 2022, closing a stake of 19,007 shares — an estimated $60K sold.

Aristides Capital first reported a position in WVE in Q4 2021 and held it in 1 quarter. The position peaked at $60K in Q4 2021. 82 funds tracked by Wall St. Rank hold WVE as of Q1 2022.

  • Aristides Capital reported no remaining Wave Life Sciences position as of Q1 2022 after selling out during the quarter.
  • Aristides Capital sold 19,007 Wave Life Sciences shares in Q1 2022, an estimated $60K.
  • Aristides Capital first reported a position in Wave Life Sciences in Q4 2021 and held it in 1 quarter.
  • Aristides Capital's Wave Life Sciences position peaked at $60K in Q4 2021.
  • 82 funds tracked by Wall St. Rank held Wave Life Sciences as of Q1 2022.

Based on Aristides Capital's 13F filing for Q1 2022, filed 16 May 2022.